VIDEO: ‘The future is bright’ for patients treated with RBX2660 for C. difficile

SAN DIEGO — In a Healio video exclusive from Digestive Disease Week 2022, Paul Feuerstadt, MD, FACG, AGAF, discussed studies assessing the investigational biotherapeutic, RBX2660, for the treatment of Clostridioides difficile.“RBX2660 has consistent safety and efficacy regardless of the patient’s medical history as well as their demographics; this again applies to the notion that patients can broadly be treated with this and have a very effective symptomatic relief of their recurrent C. difficile in a sustained fashion,” Feuerstadt, assistant clinical professor of medicineRead More

Categories: News

Related Articles

VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection

SAN DIEGO — RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to…

FDA panel votes in favor of fecal transplant therapy for recurrent C. difficile infection

An FDA advisory committee recently voted there was adequate data to support the safety and efficacy of fecal microbiota transplant therapy Rebyota for the treatment…

September 28, 2022

Environmental hygiene program halved nosocomial C. difficile infections

An environmental hygiene program meant to improve cleaning thoroughness led to a sustained 50% decrease in health care-onset Clostridioides difficile infection in eight hospitals, a…

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…

Justin Bouck July 9, 2019

Clarification on Executive Order 20-72

Below is the “official communique” that we developed with the FMA. The only addition to make is that the Board of Medicine is OK with…

Justin Bouck March 25, 2020